234 related articles for article (PubMed ID: 19101623)
1. A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase.
Natalie M; Margino S; Erik H; Annelieke P; Geert V; Philippe V
Toxicol In Vitro; 2009 Mar; 23(2):217-26. PubMed ID: 19101623
[TBL] [Abstract][Full Text] [Related]
2. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies.
Nioi P; Perry BK; Wang EJ; Gu YZ; Snyder RD
Toxicol Sci; 2007 Sep; 99(1):162-73. PubMed ID: 17567588
[TBL] [Abstract][Full Text] [Related]
3. Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential.
Kasahara T; Tomita K; Murano H; Harada T; Tsubakimoto K; Ogihara T; Ohnishi S; Kakinuma C
Toxicol Sci; 2006 Mar; 90(1):133-41. PubMed ID: 16338956
[TBL] [Abstract][Full Text] [Related]
4. High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis.
van de Water FM; Havinga J; Ravesloot WT; Horbach GJ; Schoonen WG
Toxicol In Vitro; 2011 Dec; 25(8):1870-82. PubMed ID: 21651975
[TBL] [Abstract][Full Text] [Related]
5. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays.
Mesens N; Steemans M; Hansen E; Verheyen GR; Van Goethem F; Van Gompel J
Toxicol In Vitro; 2010 Aug; 24(5):1417-25. PubMed ID: 20430096
[TBL] [Abstract][Full Text] [Related]
6. Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development.
Fujimura H; Dekura E; Kurabe M; Shimazu N; Koitabashi M; Toriumi W
Exp Toxicol Pathol; 2007 Aug; 58(6):375-82. PubMed ID: 17408938
[TBL] [Abstract][Full Text] [Related]
7. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.
Sawada H; Takami K; Asahi S
Toxicol Sci; 2005 Feb; 83(2):282-92. PubMed ID: 15342952
[TBL] [Abstract][Full Text] [Related]
8. Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats.
Miyamoto S; Matsumoto A; Mori I; Horinouchi A
Toxicol Mech Methods; 2009 Oct; 19(8):477-85. PubMed ID: 19793005
[TBL] [Abstract][Full Text] [Related]
9. In vitro assays and biomarkers for drug-induced phospholipidosis.
Monteith DK; Morgan RE; Halstead B
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):687-96. PubMed ID: 17014389
[TBL] [Abstract][Full Text] [Related]
10. A clinical flow cytometric biomarker strategy: validation of peripheral leukocyte phospholipidosis using Nile red.
Halstead BW; Zwickl CM; Morgan RE; Monteith DK; Thomas CE; Bowers RK; Berridge BR
J Appl Toxicol; 2006; 26(2):169-77. PubMed ID: 16278808
[TBL] [Abstract][Full Text] [Related]
11. Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis.
Tilmant K; Gerets HH; Dhalluin S; Hanon E; Depelchin O; Cossu-Leguille C; Vasseur P; Atienzar FA
Toxicol In Vitro; 2011 Oct; 25(7):1414-24. PubMed ID: 21515356
[TBL] [Abstract][Full Text] [Related]
12. Improved toxicogenomic screening for drug-induced phospholipidosis using a multiplexed quantitative gene expression ArrayPlate assay.
Sawada H; Taniguchi K; Takami K
Toxicol In Vitro; 2006 Dec; 20(8):1506-13. PubMed ID: 16919414
[TBL] [Abstract][Full Text] [Related]
13. Validation of an in vitro screen for phospholipidosis using a high-content biology platform.
Morelli JK; Buehrle M; Pognan F; Barone LR; Fieles W; Ciaccio PJ
Cell Biol Toxicol; 2006 Jan; 22(1):15-27. PubMed ID: 16463016
[TBL] [Abstract][Full Text] [Related]
14. A strategy for risk management of drug-induced phospholipidosis.
Chatman LA; Morton D; Johnson TO; Anway SD
Toxicol Pathol; 2009 Dec; 37(7):997-1005. PubMed ID: 20008549
[TBL] [Abstract][Full Text] [Related]
15. Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells.
Atienzar F; Gerets H; Dufrane S; Tilmant K; Cornet M; Dhalluin S; Ruty B; Rose G; Canning M
Toxicol Sci; 2007 Mar; 96(1):101-14. PubMed ID: 17175557
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced phospholipidosis.
Anderson N; Borlak J
FEBS Lett; 2006 Oct; 580(23):5533-40. PubMed ID: 16979167
[TBL] [Abstract][Full Text] [Related]
17. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening.
O'Brien PJ; Irwin W; Diaz D; Howard-Cofield E; Krejsa CM; Slaughter MR; Gao B; Kaludercic N; Angeline A; Bernardi P; Brain P; Hougham C
Arch Toxicol; 2006 Sep; 80(9):580-604. PubMed ID: 16598496
[TBL] [Abstract][Full Text] [Related]
18. Predicting phospholipidosis: a fluorescence noncell based in vitro assay for the determination of drug-phospholipid complex formation in early drug discovery.
Zhou L; Geraci G; Hess S; Yang L; Wang J; Argikar U
Anal Chem; 2011 Sep; 83(18):6980-7. PubMed ID: 21790130
[TBL] [Abstract][Full Text] [Related]
19. Hydrophilic interaction chromatography with a focus on the drug-phosphate interaction in drug screening to determine the phospholipidosis induction risk.
Okamoto H; Hamaguchi R; Kuroda Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Apr; 1051():33-40. PubMed ID: 28285021
[TBL] [Abstract][Full Text] [Related]
20. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds.
Hanumegowda UM; Wenke G; Regueiro-Ren A; Yordanova R; Corradi JP; Adams SP
Chem Res Toxicol; 2010 Apr; 23(4):749-55. PubMed ID: 20356072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]